Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.43 Analyst target: $5.25 Upside: 267.13%
BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. The company is headquartered in Santa Monica, California.
See the full interactive analysis & chart →Informational only — not investment advice.